3-Hydroxypyridin-2-thione as Novel Zinc Binding Group for Selective Histone Deacetylase Inhibition

Journal of Medicinal Chemistry

Volumn 56, Issue 9, 2013, Pages 3492-3506

  Patil, Vishal ^a   Sodji, Quaovi H ^a   Kornacki, James R ^b   Mrksich, Milan ^b   Oyelere, Adegboyega K ^a  

^a GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1,1' BIPHENYLMETHYL) 3 HYDROXYPYRIDIN 2 THIONE; 1 (4 DIMETHYLAMINO)PHENYLTRIAZOLYLMETHYL 3 HYDROXYPYRIDIN 2 THIONE; 1 [2 CYANO(1,1' BIPHENYLMETHYL)] 3 HYDROXYPYRIDIN 2 THIONE; 1 [2 METHYL(1,1' BIPHENYLMETHYL)] 3 HYDROXYPYRIDIN 2 THIONE; 1 [3 CYANO(1,1' BIPHENYLMETHYL)] 3 HYDROXYPYRIDIN 2 THIONE; 1 [3 METHYL(1,1' BIPHENYLMETHYL)] 3 HYDROXYPYRIDIN 2 THIONE; 1 [4 (PYRIDIN 4 YL)BENZYL] 3 HYDROXYPYRIDIN 2 THIONE; 1 [4 [6 (DIMETHYLAMINO)PYRIDIN 3 YL)BENZYL]]3 HYDROXYPYRIDIN 2 THIONE; 1 [4 CYANO(1,1' BIPHENYLMETHYL)] 3 HYDROXYPYRIDIN 2 THIONE; 1 [4 DIMETHYLAMINO(1,1' BIPHENYLMETHYL)] 3 HYDROXYPYRIDIN 2 THIONE; 1 [4 METHYL(1,1' BIPHENYLMETHYL)] 3 HYDROXYPYRIDIN 2 THIONE; 1 BENZYL 3 HYDROXYPYRIDIN 2 THIONE; 1 PHENYLTRIAZOLYLMETHYL 3 HYDROXYPYRIDIN 2 THIONE; 3 HYDROXYPYRIDIN 2 THIONE; ANTINEOPLASTIC AGENT; FUNCTIONAL GROUP; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE INHIBITOR; PYRIDINE DERIVATIVE; TRICHOSTATIN A; UNCLASSIFIED DRUG; VORINOSTAT;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; DRUG PROTEIN BINDING; ENZYME ACTIVE SITE; ENZYME INHIBITION; IC 50; MOLECULAR DOCKING; MOLECULAR MODEL; PHARMACOPHORE; PROCESS OPTIMIZATION; STRUCTURE ACTIVITY RELATION; WESTERN BLOTTING;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; INTRACELLULAR SPACE; MOLECULAR DOCKING SIMULATION; PROTEIN CONFORMATION; PYRIDINES; PYRIDONES; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; THIONES; ZINC;

EID: 84877701677     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm301769u     Document Type: Article

References (46)

1. Esteller, M. Cancer epigenomics: DNA methylomes and histone-modification maps Nature Rev. Genet. 2007, 8 (4) 286-298
2. Kornberg, R. D.; Lorch, Y. Twenty-Five Years of the Nucleosome, Fundamental Particle of the Eukaryote Chromosome Cell 1999, 98 (3) 285-294
3. Grunstein, M. Histone acetylation in chromatin structure and transcription Nature 1997, 389 (6649) 349-352
4. Gryder, B. E.; Sodji, Q. H.; Oyelere, A. K. Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed Future Med. Chem. 2012, 4 (4) 505-524
5. Glozak, M. A.; Sengupta, N.; Zhang, X.; Seto, E. Acetylation and deacetylation of non-histone proteins Gene 2005, 363 (0) 15-23
6. Weichert, W. HDAC expression and clinical prognosis in human malignancies Cancer Lett. 2009, 280 (2) 168-176
7. Cardinale, J. P.; Sriramula, S.; Pariaut, R.; Guggilam, A.; Mariappan, N.; Elks, C. M.; Francis, J. HDAC Inhibition Attenuates Inflammatory, Hypertrophic, and Hypertensive Responses in Spontaneously Hypertensive Rats Hypertension 2010, 56 (3) 437-444
8. Patil, V.; Guerrant, W.; Chen, P. C.; Gryder, B.; Benicewicz, D. B.; Khan, S. I.; Tekwani, B. L.; Oyelere, A. K. Antimalarial and antileishmanial activities of histone deacetylase inhibitors with triazole-linked cap group Bioorg. Med. Chem. 2010, 18 (1) 415-425
9. Rotili, D.; Simonetti, G.; Savarino, A.; Palamara, A. T.; Migliaccio, A. R.; Mai, A. Non-cancer uses of histone deacetylase inhibitors: effects on infectious diseases and beta-hemoglobinopathies Curr. Top. Med. Chem. 2009, 9 (3) 272-291
10. Chuang, D.-M.; Leng, Y.; Marinova, Z.; Kim, H.-J.; Chiu, C.-T. Multiple roles of HDAC inhibition in neurodegenerative conditions Trends Neurosci. 2009, 32 (11) 591-601
11. Miller, T. A.; Witter, D. J.; Belvedere, S. Histone Deacetylase Inhibitors J. Med. Chem. 2003, 46 (24) 5097-5116
12. Finnin, M. S.; Donigian, J. R.; Cohen, A.; Richon, V. M.; Rifkind, R. A.; Marks, P. A.; Breslow, R.; Pavletich, N. P. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors Nature 1999, 401 (6749) 188-193
13. Jerry, W. S.; Nina, C. G.; Arco, Y. J. The Design, Structure, and Clinical Update of Small Molecular Weight Matrix Metalloproteinase Inhibitors Curr. Med. Chem. 2004, 11 (22) 2911-2977
14. Whittaker, M.; Floyd, C. D.; Brown, P.; Gearing, A. J. H. Design and Therapeutic Application of Matrix Metalloproteinase Inhibitors Chem. Rev. 1999, 99 (9) 2735-2776
15. Reiter, L. A.; Robinson, R. P.; McClure, K. F.; Jones, C. S.; Reese, M. R.; Mitchell, P. G.; Otterness, I. G.; Bliven, M. L.; Liras, J.; Cortina, S. R.; Donahue, K. M.; Eskra, J. D.; Griffiths, R. J.; Lame, M. E.; Lopez-Anaya, A.; Martinelli, G. J.; McGahee, S. M.; Yocum, S. A.; Lopresti-Morrow, L. L.; Tobiassen, L. M.; Vaughn-Bowser, M. L. Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1 Bioorg. Med. Chem. Lett. 2004, 14 (13) 3389-3395
16. Frey, R. R.; Wada, C. K.; Garland, R. B.; Curtin, M. L.; Michaelides, M. R.; Li, J.; Pease, L. J.; Glaser, K. B.; Marcotte, P. A.; Bouska, J. J.; Murphy, S. S.; Davidsen, S. K. Trifluoromethyl ketones as inhibitors of histone deacetylase Bioorg. Med. Chem. Lett. 2002, 12 (23) 3443-3447
17. Coussens, L. M.; Fingleton, B.; Matrisian, L. M. Matrix Metalloproteinase Inhibitors and Cancer-Trials and Tribulations Science 2002, 295 (5564) 2387-2392
18. Farkas, E.; Katz, Y.; Bhusare, S.; Reich, R.; Röschenthaler, G.-V.; Königsmann, M.; Breuer, E. Carbamoylphosphonate-based matrix metalloproteinase inhibitor metal complexes: solution studies and stability constants. Towards a zinc-selective binding group J. Biol. Inorg. Chem. 2004, 9 (3) 307-315
19. O'Brien, E. C.; Farkas, E.; Gil, M. J.; Fitzgerald, D.; Castineras, A.; Nolan, K. B. Metal complexes of salicylhydroxamic acid (H2Sha), anthranilic hydroxamic acid and benzohydroxamic acid. Crystal and molecular structure of [Cu(phen)2(Cl)]Cl·H2Sha, a model for a peroxidase-inhibitor complex J. Inorg. Biochem. 2000, 79 (1-4) 47-51
20. Oyelere, A. K.; Chen, P. C.; Guerrant, W.; Mwakwari, S. C.; Hood, R.; Zhang, Y.; Fan, Y. Non-Peptide Macrocyclic Histone Deacetylase Inhibitors J. Med. Chem. 2008, 52 (2) 456-468
21. Butler, K. V.; Kalin, J.; Brochier, C.; Vistoli, G.; Langley, B.; Kozikowski, A. P. Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A J. Am. Chem. Soc. 2010, 132 (31) 10842-10846
22. Suzuki, T.; Miyata, N. Non-hydroxamate Histone Deacetylase Inhibitors Curr. Med. Chem. 2005, 12 (24) 2867-2880
23. Khan, N.; Jeffers, M.; Kumar, S.; Hackett, C.; Boldog, F.; Khramtsov, N.; Qian, X. Z.; Mills, E.; Berghs, S. C.; Carey, N.; Finn, P. W.; Collins, L. S.; Tumber, A.; Ritchie, J. W.; Jensen, P. B.; Lichenstein, H. S.; Sehested, M. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors Biochem. J. 2008, 409, 581-589
24. Saito, A.; Yamashita, T.; Mariko, Y.; Nosaka, Y.; Tsuchiya, K.; Ando, T.; Suzuki, T.; Tsuruo, T.; Nakanishi, O. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors Proc. Natl. Acad. Sci. U. S. A. 1999, 96 (8) 4592-4597
25. Monneret, C. Histone deacetylase inhibitors Eur. J. Med. Chem. 2005, 40 (1) 1-13
26. Jacobsen, F. E.; Lewis, J. A.; Cohen, S. M. The Design of Inhibitors for Medicinally Relevant Metalloproteins ChemMedChem 2007, 2 (2) 152-171
27. Puerta, D. T.; Lewis, J. A.; Cohen, S. M. New Beginnings for Matrix Metalloproteinase Inhibitors: Identification of High-Affinity Zinc-Binding Groups J. Am. Chem. Soc. 2004, 126 (27) 8388-8389
28. Lewis, J. A.; Tran, B. L.; Puerta, D. T.; Rumberger, E. M.; Hendrickson, D. N.; Cohen, S. M. Synthesis, structure and spectroscopy of new thiopyrone and hydroxypyridinethione transition-metal complexes Dalton Trans. 2005, 15, 2588-2596
29. Somoza, J. R.; Skene, R. J.; Katz, B. A.; Mol, C.; Ho, J. D.; Jennings, A. J.; Luong, C.; Arvai, A.; Buggy, J. J.; Chi, E.; Tang, J.; Sang, B.-C.; Verner, E.; Wynands, R.; Leahy, E. M.; Dougan, D. R.; Snell, G.; Navre, M.; Knuth, M. W.; Swanson, R. V.; McRee, D. E.; Tari, L. W. Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases Structure 2004, 12 (7) 1325-1334
30. Mwakwari, S. C.; Guerrant, W.; Patil, V.; Khan, S. I.; Tekwani, B. L.; Gurard-Levin, Z. A.; Mrksich, M.; Oyelere, A. K. Non-Peptide Macrocyclic Histone Deacetylase Inhibitors Derived from Tricyclic Ketolide Skeleton J. Med. Chem. 2010, 53 (16) 6100-6111
31. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function J. Comput. Chem. 1998, 19 (14) 1639-1662
32. Davies, J. S.; Smith, K.; Turner, J. Novel heterocyclic systems, Part 4: A simple, convenient synthesis of 3-hydroxypyridine-2-thione, and the preparation of two novel tricyclic betaines Tetrahedron Lett. 1980, 21 (22) 2191-2194
33. Gurard-Levin, Z. A.; Mrksich, M. The Activity of HDAC8 Depends on Local and Distal Sequences of Its Peptide Substrates Biochemistry 2008, 47 (23) 6242-6250
34. Gurard-Levin, Z. A.; Scholle, M. D.; Eisenberg, A. H.; Mrksich, M. High-Throughput Screening of Small Molecule Libraries using SAMDI Mass Spectrometry ACS Comb. Sci. 2011, 13 (4) 347-350
35. Srogl, J.; Liu, W.; Marshall, D.; Liebeskind, L. S. Bio-organometallic Organosulfur Chemistry. Transition Metal-Catalyzed Cross-Coupling Using Coenzyme M or Thioglycolic Acid as the Leaving Group J. Am. Chem. Soc. 1999, 121 (40) 9449-9450
36. Miyaura, N.; Yamada, K.; Suzuki, A. A new stereospecific cross-coupling by the palladium-catalyzed reaction of 1-alkenylboranes with 1-alkenyl or 1-alkynyl halides Tetrahedron Lett. 1979, 20 (36) 3437-3440
37. Egan, W. J.; Lauri, G. Prediction of intestinal permeability Adv. Drug Delivery Rev. 2002, 54 (3) 273-289
38. Guerrant, W.; Patil, V.; Canzoneri, J. C.; Oyelere, A. K. Dual Targeting of Histone Deacetylase and Topoisomerase II with Novel Bifunctional Inhibitors J. Med. Chem. 2012, 55 (4) 1465-1477
39. Namdar, M.; Perez, G.; Ngo, L.; Marks, P. A. Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents Proc. Natl. Acad. Sci. U. S. A. 2010, 107 (46) 20003-20008
40. Yamaki, H.; Nakajima, M.; Shimotohno, K. W.; Tanaka, N. Molecular basis for the actions of Hsp90 inhibitors and cancer therapy J. Antibiot. 2011, 64 (9) 635-644
41. Balasubramanian, S.; Ramos, J.; Luo, W.; Sirisawad, M.; Verner, E.; Buggy, J. J. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas Leukemia 2008, 22 (5) 1026-1034
42. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 1997, 23 (1-3) 3-25
43. Kerns, E. H.; Di, L.; Carter, G. T. In Vitro Solubility Assays in Drug Discovery Curr. Drug Metab. 2008, 9 (9) 879-885
44. Kulp, S. K.; Chen, C.-S.; Wang, D.-S.; Chen, C.-Y.; Chen, C.-S. Antitumor Effects of a Novel Phenylbutyrate-Based Histone Deacetylase Inhibitor, (S)-HDAC-42, in Prostate Cancer Clin. Cancer Res. 2006, 12 (17) 5199-5206
45. Chakraborty, A.; Dey, S.; Sawoo, S.; Adarsh, N. N.; Sarkar, A. Regioselective 1,3-Dipolar Cycloaddition Reaction of Azides with Alkoxy Alkynyl Fischer Carbene Complexes Organometallics 2010, 29 (23) 6619-6622
46. Andersen, J.; Bolvig, S.; Liang, X. Efficient One-Pot Synthesis of 1-Aryl 1,2,3-Triazoles from Aryl Halides and Terminal Alkynes in the Presence of Sodium Azide Synlett 2005, 2005 (EFirst) 2941-2947